| Test | Normal Reserve | Diminished Reserve | High Reserve / Risk |
|---|---|---|---|
| AMH (Anti-Mullerian Hormone) | 1.5 – 4.0 ng/mL | < 1.0 ng/mL | > 4.5 ng/mL (OHSS risk) |
| AFC (Antral Follicle Count) | 7 – 15 follicles | < 5–7 follicles | > 20 follicles (PCO morphology) |
| Day 3 FSH | < 10 IU/L | > 10–12 IU/L | — |
| Day 3 Oestradiol (E2) | < 60–80 pg/mL | > 80 pg/mL (false-low FSH) | — |
| Clomiphene Challenge Test (CCCT) | Day 10 FSH < 10 | Day 10 FSH > 10 | — |
| Parameter | Lower Limit |
|---|---|
| Volume | ≥ 1.4 mL |
| Sperm concentration | ≥ 16 × 10⁶/mL |
| Total motility (PR + NP) | ≥ 42% |
| Progressive motility (PR) | ≥ 30% |
| Morphology (Kruger strict) | ≥ 4% normal forms |
| Total sperm number | ≥ 39 × 10⁶ / ejaculate |
| Vitality (live) | ≥ 54% |
Diagnosis requires 2 of 3 criteria:
<8 cycles/year or cycles >35 days; absent LH surge on tracking
Hirsutism (Ferriman-Gallwey ≥8), acne, elevated free testosterone/DHEAS; exclude CAH, Cushing, androgen tumour
AFC ≥20 per ovary OR ovarian volume ≥10 mL on transvaginal US (exclude dominant follicle, CL)
| Trigger Type | Dose | Timing | Best For | OHSS Risk |
|---|---|---|---|---|
| Urinary hCG (Pregnyl, Profasi) | 5,000–10,000 IU SC/IM | Exact time — OPU 34–36 hrs later | Agonist protocol, normal responders | High |
| Recombinant hCG (Ovitrelle) | 250 mcg SC | Exact time — OPU 34–36 hrs later | Agonist protocol, more predictable | High |
| GnRH Agonist (Buserelin, Triptorelin) | 0.2–0.5 mg SC | Exact time — OPU 34–36 hrs later | Antagonist protocol, PCOS, high responders | Low |
| Dual Trigger (hCG + GnRH-a) | Standard doses combined | Simultaneous, exact time | Poor responders (IVF optimisation) | Moderate |
| Route | Example | Dose | Notes |
|---|---|---|---|
| Vaginal pessary | Cyclogest, Utrogestan | 400–800 mg/day | First-line; minimal systemic SE |
| Vaginal gel | Crinone 8% | Once daily | Good compliance |
| IM injection | Progesterone in oil | 50 mg/day | Painful; used if vaginal contraindicated |
| Subcutaneous | Prolutex | 25 mg/day | Well tolerated, expensive |
| Oral | Utrogestan oral | 200–300 mg/day | Adjunct only; poor bioavailability |
Continue until 10–12 weeks gestation if positive hCG; taper after first trimester once placenta established. Never stop abruptly — taper under physician direction.
| Parameter | Frequency | Alert Threshold |
|---|---|---|
| Abdominal girth | Every 12 hrs | Increase >3 cm in 24 hrs |
| Daily weight | Every 24 hrs (same time) | Gain >1 kg/24 hrs |
| Fluid balance | Strict hourly urine output | UO <30 mL/hr for 2 hrs |
| Haematocrit | Daily (BD if severe) | >45% (severe), >55% (critical) |
| Creatinine / eGFR | Daily | Rising trend or Cr >133 µmol/L |
| Electrolytes | Daily | Hyponatraemia <130, hyperkalaemia |
| WBC | Daily | >25,000 (severe response) |
| SpO2 | Continuous if severe | <95% |
| Visit | Assessment | Action |
|---|---|---|
| Day 2–3 | Baseline US + E2 | Start oestradiol 6 mg/day oral or patches |
| Day 8–10 | Endometrial thickness + pattern | Target: ≥7 mm trilaminar (triple-line) |
| Pre-progesterone | Final US + E2 (aim >200 pg/mL) | If adequate: start progesterone |
| ET Day | Final check US (no fluid, thickness) | Proceed or defer |
First beta-hCG: typically Day 9–12 post-ET. Doubling time normal: <48–72 hours in early viable intrauterine pregnancy.
| Beta-hCG Level | Interpretation |
|---|---|
| <5 IU/L | Negative |
| 5–25 IU/L | Equivocal — repeat 48 hrs |
| >25 IU/L (Day 9) | Positive — monitor trend |
| >1000–1500 IU/L | US discriminatory zone — expect gestational sac |
| >6500 IU/L | Foetal heartbeat expected on US |
IVF permitted exclusively for legally married heterosexual couples. Islamic fatwa (NCBE 1985) permits IVF using husband's sperm and wife's oocyte only. Gamete donation strictly prohibited. Surrogacy prohibited. Embryo freezing permitted. All centres must be licensed by Ministry of Health (MOH). Saudi Commission for Health Specialties (SCFHS) oversees fertility specialists. Genetic screening (PGT) allowed for hereditary diseases with MOH approval.
Regulated under Federal Law No. 11 (2008) — IVF for married couples using own gametes only. MOHAP (Ministry of Health and Prevention) licenses all ART centres. Abu Dhabi DOH and Dubai Health Authority (DHA) have additional oversight. Embryo freezing, ICSI, PGT widely available. Third-party donation and surrogacy prohibited. Major centres: IVF.ae, Bourn Hall Dubai, ICSI Fertility, Fakih IVF (Abu Dhabi), Al Ain Fertility Centre.
Supreme Council of Health oversees ART services. IVF for married couples only — own gametes required. Hamad Medical Corporation (HMC) leads fertility services. Sharia-compliant regulations similar to KSA. Embryo freezing for personal use permitted. PGT available for genetic disease prevention. No donor gametes or surrogacy.
Ministry of Health regulates ART. IVF permitted for married couples using their own gametes. Law No. 34/1987 governs medical practice; ART follows Islamic guidance. Bneid Al-Gar Hospital and private centres offer IVF. Third-party reproduction prohibited. Embryo freezing commonly practiced.
National Health Regulatory Authority (NHRA) licenses IVF centres. IVF for married couples; own gametes only. Comparatively more liberal in accessibility of ART services. Private clinics (e.g., BNH, Bahrain Specialist Hospital fertility unit) operate under NHRA. No gamete donation or surrogacy.
Ministry of Health regulates ART. IVF for married couples using own gametes. Royal Hospital Muscat and private clinics offer services. Islamic principles govern all ART decisions. No donor gametes or surrogacy. Embryo freezing permitted within Islamic guidelines.
Dedicated IVF centre, DHA licensed. Offers full ART services, PGT-A, vitrification, and fertility preservation for oncology patients.
Internationally recognised (Cambridge origins). Offers IVF, ICSI, blastocyst culture, frozen embryo transfer. DHA licensed.
Long-established in Abu Dhabi Emirate. Caters to Emirati and expatriate population. MOHAP licensed.
One of UAE's largest ART networks. Extensive experience, multilingual team, Islamic advisory board.
Comprehensive reproductive medicine unit. MOH/NCBE compliant. Serves Saudi nationals and expatriates.
Leading public fertility services in Qatar. Part of HMC network. Sharia-compliant ART under MOH oversight.
| Concern | Nurse Response |
|---|---|
| Needle phobia | Pen devices available; autoinjectors; desensitisation counselling; partner training |
| Bruising/redness | Normal; rotate sites; cold compress before injection; avoid same spot |
| Missed dose | Contact clinic immediately; do not double dose; protocol-specific guidance |
| Medication ran out early | Emergency prescription; never skip FSH dose — follicular development depends on continuous stimulation |
| Air bubble in syringe | Small bubbles (SC): safe, harmless. Remove large bubbles by pointing up and tapping gently |
Store 2–8°C (refrigerator). Do NOT freeze. Once reconstituted/opened: use within 28 days (pen) or immediately (vial). Keep away from direct light. Examples: Gonal-F, Bemfola, Puregon, Menopur.
Room temperature (up to 25°C) for most preparations. Nasal sprays: store upright. Cetrorelix/ganirelix pre-filled syringes: refrigerate until use then allow to warm slightly. Check package insert for each brand.
hCG powder: room temperature; reconstitute with provided solvent immediately before use. Ovitrelle pre-filled pen: refrigerate. Cyclogest pessaries: below 25°C, away from heat. Progesterone in oil: room temperature.